Monthly Archives April 2021

IIT Kharagpur Launches COVIRAP Diagnostic Technology | Latest India News

IIT Kharagpur has successfully marketed its flagship healthcare product COVIRAP, the new zero-diagnostic technology for infectious diseases, including Covid-19, the institute said on Wednesday.

The product, developed by Principal Investigators Professor Suman Chakraborty, Dr Arindam Mondal and their research group, has been licensed for the Rapid Diagnostic Group of Companies, India and Bramerton Holdings LLC, USA.

A virtual press meeting was organized on Wednesday by the institute in which the researchers were present as well as the director of the institute to make the announcement.

“The above decision came at a critical time when the recent surge of Covid-19 infection, commonly known as the second wave, threatened to spread faster than ever before,” said the director of IIT Kharagpur, Professor VK Tewari.

“Additionally, the commercialization of COVIRAP will initiate full indigenization and availability of a wide range of affordable health products in the Indian market as well as the deep trenches of a large global market that literally needs such technology. Tewari said.

Bramerton Holdings has signed a record-breaking deal to secure the worldwide rights to commercialize COVIRAP technology developed at IIT Kharagpur in various geographies outside of the Indian subcontinent, a spokesperson for the institute said.

Rapid Diagnostic has also initiated the adaptation of the COVIRAP technology platform for Covid-19 and tuberculosis, in collaboration with IIT Kharagpur, the spokesperson said.

The research team has now developed a more advanced version of COVIRAP using isothermal step-by-step nucleic acid testing technology for the rapid diagnosis of pathogenic infections, including SARS-CoV-2 in individuals, Chakraborty said. .

The Covid-19 diagnostic test can be performed directly from human swab samples in the portable device developed by the team, without requiring a separate facility for RNA extraction.

Results may be available within 45 minutes of obtaining the sample from the patient, he said.

The kit has also been supplemented with a free smartphone app to facilitate unambiguous interpretation of results and automated delivery to patients.

For the use of the test, nasal samples as well as oral swabs are diluted in a solution and tested in the portable device by mixing them with reagents provided in a pre-mixed form, Chakraborty said, adding that the test s ‘automatically executed in the device without intermediate manual intervention.

“We conducted field trials to run the tests with the help of unqualified personnel outside of a controlled laboratory environment, without compromising the quality of the test result. The entire sample-result procedure can be performed in the handheld device, virtually anywhere and with minimal training, making the testing process more efficient for community-level screening and early detection of any outbreak. emerging infection.

“This can serve as a key to stop the spread of infection at the community level,” Chakraborty hopes.

COVIRAP promises its reach at the local level by meeting the needs of the last person in society, he added.

The researchers claimed that the COVIRAP test overcomes several potential bottlenecks encountered by other similar tests in the past, for example, poor performance outside a highly controlled laboratory and the lack of simple, affordable instruments, but generic and universal that can be used for home and community testing. healthcare for a wide variety of infectious and non-infectious diseases.

Recognizing the impact of COVIRAP technology in meeting longstanding demands for high quality testing at the community level, IIT Kharagpur further initiated the process of deploying this product for use on campus to detect possible new coronavirus infection, the institute spokesperson said. .

Patents centered around this innovation have been filed in India, in the USA, in several other countries, in the name of IIT Kharagpur.

The foreign deposit license was granted recently.

Marketing and use in the United States and Europe under the Emergency Use Authorization (EUA) process is currently underway.


Source link

Coronavirus | IIT Kharagpur launches COVIRAP diagnostic technology

Results may be available within 45 minutes of obtaining the patient sample.

IIT Kharagpur has successfully commercialized its flagship healthcare product COVIRAP, the new zero-diagnostic technology for infectious diseases, including COVID-19, the institute said on Wednesday.

The product, developed by Principal Investigators Professor Suman Chakraborty, Dr Arindam Mondal and their research group, has been licensed for the Rapid Diagnostic Group of Companies, India and Bramerton Holdings LLC, USA.

A virtual press meeting was organized on Wednesday by the institute in which the researchers were present as well as the director of the institute to make the announcement.

“The above decision came at a critical time when the recent surge of COVID-19 infection, commonly known as the second wave, threatened to spread faster than ever before,” said the director of IIT Kharagpur, Professor VK Tewari.

“Further, the commercialization of COVIRAP will initiate full indigenization and the availability of a wide range of affordable health products in the Indian market as well as the deep trenches of a large global market that is literally starved for the need for such technology, ”Mr. Tewari mentioned.

Bramerton Holdings has signed a record-breaking deal to secure the worldwide rights to commercialize COVIRAP technology developed at IIT Kharagpur in various geographies outside of the Indian subcontinent, a spokesperson for the institute said.

Rapid Diagnostic has also initiated the adaptation of the COVIRAP technology platform for COVID-19 and tuberculosis, in collaboration with IIT Kharagpur, the spokesperson said.

The research team has now developed a more advanced version of COVIRAP using isothermal step-by-step nucleic acid testing technology for the rapid diagnosis of pathogenic infections, including SARS-CoV-2 in individuals, said M Chakraborty.

The COVID-19 diagnostic test can be performed directly from human swab samples in the portable device developed by the team, without requiring a separate facility for RNA extraction.

Results in 45 minutes

Results may be available within 45 minutes of obtaining the sample from the patient, he said.

The kit has also been supplemented with a free smartphone app to facilitate unambiguous interpretation of results and automated delivery to patients.

For the use of the test, nasal samples as well as oral swabs are diluted in a solution and tested in the portable device by mixing them with reagents provided in a pre-mixed form, Chakraborty said, adding the tests. . automatically in the device without intermediate manual intervention.

“We conducted field trials to run the tests with the help of unqualified personnel outside of a controlled laboratory environment, without compromising the quality of the test result. The entire sample-result procedure can be performed in the handheld device, virtually anywhere and with minimal training, making the testing process more efficient for community-level screening and early detection of any outbreak. emerging infection.

“This can serve as a key to stop the spread of infection at the community level,” Chakraborty hoped.

COVIRAP promises its reach at the local level by meeting the needs of the last person in society, he added.

The researchers claimed that the COVIRAP test overcomes several potential bottlenecks encountered by other similar tests in the past, for example, poor performance outside a highly controlled laboratory and the lack of simple, affordable instruments, but generic and universal that can be used for home and community testing. healthcare for a wide variety of infectious and non-infectious diseases.

Recognizing the impact of COVIRAP technology in meeting longstanding demands for high quality testing at the community level, IIT Kharagpur further initiated the process of deploying this product for use on campus to detect possible new coronavirus infection, the institute spokesperson said. .

Patents centered around this innovation have been filed in India, in the USA, in several other countries, in the name of IIT Kharagpur.

The foreign deposit license was granted recently.

Marketing and use in the United States and Europe under the Emergency Use Authorization (EUA) process is currently underway.


Source link

Mayo Clinic Launches Joint Ventures to Create and Market AI Diagnostic Tools

James R. Martin / Shutterstock

Mayo Clinic announced wednesday that he has launched two new technology companies designed to harness artificial intelligence (AI) and medical algorithms to create “software as medical devices” that clinicians can use to improve the treatment of different diseases.

The two new companies – Anumana Inc. and Lucem Health Inc. – were launched with a $ 30 million investment from the Mayo Clinic and its venture capital partners.

Anumana completed a $ 25.7 million Series A funding round, led by founding organizations nference and Mayo Clinic and in collaboration with Matrix Capital Management, Matrix Partners and NTVC.

Lucem Health closed a $ 6 million Series A funding round ahead of its launch, led by founders Commure and Mayo Clinic.

In a statement from the Mayo Clinic, the two new tech companies will focus on providing next-generation clinical decision support tools, diagnostic information and care recommendations. Both companies’ AI and medical algorithms will use Mayo Clinic’s medical knowledge, gathered from the organization’s patient records, to develop digital tools that will provide better treatment options for patients with various illnesses.

The companies will leverage Mayo Clinic’s Remote Diagnosis and Management (RDMP) platform, which connects data to innovative new AI algorithms and works to influence clinician decision-making to improve care .

“The dramatically increased use of remote patient telemetry devices, coupled with the rapid acceleration in the development of AI and machine learning algorithms, has the potential to revolutionize diagnostic medicine,” said John Halamka, MD, chair of the Mayo Clinic platform. “With RDMP, clinicians will have access to the best algorithms and care protocols and will be able to serve more patients effectively in remote care environments. The platform will also allow patients to have better control over their health and make better decisions based on the information provided directly to them. “

Anumana will work on the development and commercialization of new digital sensor diagnostic tools using a combination of nference AI and the Mayo Clinic medical data repository. Initially, the new company will focus on developing cutting-edge neural network algorithms, incorporating billions of heart health data from Mayo Clinic’s clinical data analysis platform. This work aims to uncover new biomedical knowledge regarding cardiovascular problems, thus facilitating early detection and better treatments for heart disease.

“For many conditions, such as a weak or thickened heart pump, or silent arrhythmias, there are effective, evidence-based treatments that can prevent heart failure, stroke or death,” Paul said. Friedman, MD, chairman of the Mayo Clinic Department of Cardiovascular Medicine. “The key is to detect the disease before symptoms develop to prevent these events from occurring. The addition of AI to the ECG, a ubiquitous and inexpensive point-of-care test that is already integrated in medical workflows, makes this approach good for patients, convenient for clinicians and extremely scalable. “

The co-founder and CEO of nference and CEO of Anumana, Murali Aravamudan, added, “Our augmented intelligence technology, in the hands of scientific and clinical experts, will enable a complete translation of the language of the heart. We regard it as the Rosetta Stone for cardiac medicine. “

Lucem Health was launched by the Commure and Mayo Clinic to provide the platform that will connect remote patient telemetry devices with algorithms enhanced by AI technology. Ultimately, the company plans to integrate all of the diagnostic information generated from these algorithms into real-world clinical workflows.

“Lucem Health exists to help innovations in diagnostic medicine come to life,” said Sean Cassidy, founding CEO of Lucem Health. “We are excited to be working with partners like the Mayo Clinic and Anumana who are reinventing the way we detect and treat disease. “


Source link